Tag Archives: Bloomberg

Eureka Thera’s CAR-T treatment shrinks liver cancer in small study. What’s the big deal? Just ask Sloan-Kettering and Germany’s Boehringer.

The News: Eureka Therapeutics Inc., a closely held biotechnology company, said that liver cancer patients getting its CAR-T therapy responded to the treatment, one of the first times the immune-system… Read more »

Forget about Biogen/Eisai’s promising new drug for Alzheimer’s; Study says aggressive blood-pressure treatment with existing meds reduces dementia/AD risk.

The News: After decades of prominent failures, hope arose for a drug to slow the progression of Alzheimer’s disease (AD). After heightening expectations recently, Eisai Co. Ltd. (Tokyo) and Biogen… Read more »

Tiny Swedish biotech not taking back seat to US in Alzheimer’s race. How to buy it.

The News: BioArctic AB, based in Stockholm, said it has clinical results showing its antibody treatment that targets amyloid plaques, a hallmark of Alzheimer’s disease, can slow the disease’s progression. The trial… Read more »

Wondering why some of your Pharma shares keep going up? Thank Trump’s tax “reform;” no, really.

The News: The drug industry has taken heat from patient advocates and a US senator for handing out its tax savings to shareholders instead of using its windfall to help patients… Read more »

Warren Buffett’s bluster about new healthcare venture bound to backfire. Then what?

The News: Warren Buffett says his joint venture with Jeff Bezos and Jamie Dimon is going for something bigger than shaving a few percentage points off healthcare costs. The big… Read more »

South Korea’s Celltrion Inc. (Incheon) gets EU green light for Herceptin biosimilar

The News: Celltrion Inc. said on February 14, 2018 that it has received approval to sell its replica version of Roche Holding AG’s (Basel CHE) breast-cancer blockbuster Herceptin in Europe…. Read more »

China’s FDA to accept foreign trial data for accelerated approvals; sounds great, but future enforcement of IP rights poses threat to US Pharma.

The News: For decades, patients in China have fought to gain access to cutting-edge medicines thanks to bureaucratic delays that have thwarted drug development. Now a sweeping government overhaul of… Read more »

Catabasis soars on fresh Duchenne trial data, proving biotech melt-up still in progress; but for how much longer?

The News: Recuperating from a trial flop involving its lead drug for Duchenne muscular dystrophy, Catabasis Pharmaceuticals Inc. (Cambridge MA) is charging ahead with a late-stage study, hyping new data… Read more »

Humdrum, stodgy Pfizer suddenly turns heads with partial drug-pipeline spinoff; old dog apparently can learn new tricks.

The News: Pfizer Inc. (NYC) on Monday (September 25, 2017) announced that it is spinning off a new company, SpringWorks Therapeutics LLC, to develop several drugs for rare diseases that… Read more »